182 related articles for article (PubMed ID: 27644332)
1. Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
Falasca M; Hamilton JR; Selvadurai M; Sundaram K; Adamska A; Thompson PE
J Med Chem; 2017 Jan; 60(1):47-65. PubMed ID: 27644332
[TBL] [Abstract][Full Text] [Related]
2. Class II PI3K Functions in Cell Biology and Disease.
Gulluni F; De Santis MC; Margaria JP; Martini M; Hirsch E
Trends Cell Biol; 2019 Apr; 29(4):339-359. PubMed ID: 30691999
[TBL] [Abstract][Full Text] [Related]
3. Combined deficiency of PI3KC2α and PI3KC2β reveals a nonredundant role for PI3KC2α in regulating mouse platelet structure and thrombus stability.
Petitjean C; Setiabakti NM; Mountford JK; Arthur JF; Ellis S; Hamilton JR
Platelets; 2016 Jul; 27(5):402-9. PubMed ID: 26943229
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics.
Ribes A; Oprescu A; Viaud J; Hnia K; Chicanne G; Xuereb JM; Severin S; Gratacap MP; Payrastre B
Biochem J; 2020 Nov; 477(22):4327-4342. PubMed ID: 33242335
[TBL] [Abstract][Full Text] [Related]
5. Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.
Mavrommati I; Cisse O; Falasca M; Maffucci T
Sci Rep; 2016 Mar; 6():23277. PubMed ID: 26983806
[TBL] [Abstract][Full Text] [Related]
6. Regulation and cellular functions of class II phosphoinositide 3-kinases.
Falasca M; Maffucci T
Biochem J; 2012 May; 443(3):587-601. PubMed ID: 22507127
[TBL] [Abstract][Full Text] [Related]
7. Classes of phosphoinositide 3-kinases at a glance.
Jean S; Kiger AA
J Cell Sci; 2014 Mar; 127(Pt 5):923-8. PubMed ID: 24587488
[TBL] [Abstract][Full Text] [Related]
8. PI3K signalling in inflammation.
Hawkins PT; Stephens LR
Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
[TBL] [Abstract][Full Text] [Related]
9. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Class II Phosphoinositide 3-Kinases.
Heng EYZ; Maffucci T
Curr Top Microbiol Immunol; 2022; 436():51-68. PubMed ID: 36243839
[TBL] [Abstract][Full Text] [Related]
11. Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis.
Tibolla G; Piñeiro R; Chiozzotto D; Mavrommati I; Wheeler AP; Norata GD; Catapano AL; Maffucci T; Falasca M
PLoS One; 2013; 8(1):e53808. PubMed ID: 23320105
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.
Boller D; Doepfner KT; De Laurentiis A; Guerreiro AS; Marinov M; Shalaby T; Depledge P; Robson A; Saghir N; Hayakawa M; Kaizawa H; Koizumi T; Ohishi T; Fattet S; Delattre O; Schweri-Olac A; Höland K; Grotzer MA; Frei K; Spertini O; Waterfield MD; Arcaro A
Anticancer Res; 2012 Aug; 32(8):3015-27. PubMed ID: 22843869
[TBL] [Abstract][Full Text] [Related]
13. Class II phosphoinositide 3-kinase C2alpha: what we learned so far.
Mazza S; Maffucci T
Int J Biochem Mol Biol; 2011; 2(2):168-182. PubMed ID: 21968800
[TBL] [Abstract][Full Text] [Related]
14. Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
Vanhaesebroeck B; Whitehead MA; Piñeiro R
J Mol Med (Berl); 2016 Jan; 94(1):5-11. PubMed ID: 26658520
[TBL] [Abstract][Full Text] [Related]
15. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo.
Smith GC; Ong WK; Rewcastle GW; Kendall JD; Han W; Shepherd PR
Biochem J; 2012 Feb; 442(1):161-9. PubMed ID: 22142257
[TBL] [Abstract][Full Text] [Related]
16. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Bago R; Malik N; Munson MJ; Prescott AR; Davies P; Sommer E; Shpiro N; Ward R; Cross D; Ganley IG; Alessi DR
Biochem J; 2014 Nov; 463(3):413-27. PubMed ID: 25177796
[TBL] [Abstract][Full Text] [Related]
17. Class II phosphatidylinositol 3-kinase isoforms in vesicular trafficking.
Yoshioka K
Biochem Soc Trans; 2021 Apr; 49(2):893-901. PubMed ID: 33666217
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting PI3K as a therapeutic strategy against cancer.
Paz-Ares L; Blanco-Aparicio C; García-Carbonero R; Carnero A
Clin Transl Oncol; 2009 Sep; 11(9):572-9. PubMed ID: 19775996
[TBL] [Abstract][Full Text] [Related]
19. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
Ghigo A; Hirsch E
Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide 3-kinases in health and disease.
Ghigo A; Morello F; Perino A; Hirsch E
Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
